Healthtech Pigeon Can precision diagnostics be made more accessible?
Mar 1, 2026
Celestin de Wergifosse, CEO of Signature Biosciences, builds PCR kits to bring gene-expression tests into hospital labs. Christoph Ruedig, Albion VC partner and former physician, invests in early-stage healthtech. They discuss making precision diagnostics run on existing lab equipment, tackling cost and scaling bottlenecks, integrating tests into clinical workflows, and the sensible roles and risks of AI and wearables.
AI Snips
Chapters
Transcript
Episode notes
Turn Centralized Genomics Into In-House PCR Kits
- Signature Biosciences repurposes standard qPCR machines to run complex gene-expression diagnostics in-hospital instead of centralized labs.
- That converts $2k–$5k, 1–3 week tests into simple PCR kits run on existing hospital infrastructure with fast turnaround.
Choose Awards That Offer Practical Startup Support
- Take award opportunities that combine visibility, mentorship, office space and clinical introductions.
- Celestin cited the Health Tech Pioneer prize as timing-perfect: VC mentorship, office residency and hospital network intros helped rapid growth.
Partnerships Reveal The Right First Clinical Use Case
- Startup–provider partnerships accelerate product-market fit by exposing founders to real clinical problems.
- Albion and Harley Street link capital, hospital networks and provider feedback to help founders prioritize the first clinical test.